SCHEMBL6777196

SCHEMBL6777196

NN=CNc1cccc(C(=O)NCC(=O)NC(CC(=O)O)c2cc3ccccc3o2)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.47
ITGB3 P05106 16/20 0.44
ITGAV P06756 15/20 0.44
ITGB1 P05556 10/20 0.44
ITGA5 P08648 10/20 0.44
MDM2 Q00987 6/20 0.44
MDM4 O15151 4/20 0.44
ITGB6 P18564 7/20 0.42
ITGB5 P18084 3/20 0.42
ITGB8 P26012 3/20 0.42
ITGA8 P53708 3/20 0.42
ITGA2B P08514 1/20 0.40
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6777182 0.86 RXFP1 (0.52) RXFP1ITGB3ITGAVITGB1ITGA5
SCHEMBL6782755 0.86 ITGB3 (0.51) ITGB3ITGAVITGB1ITGA5MDM2
SCHEMBL7342043 0.85 PIN1 (0.55) RXFP1ITGB3ITGAVITGB1ITGA5
SCHEMBL7836882 0.85 ITGB3 (0.48) ITGB3ITGAVITGB1ITGA5MDM2
SCHEMBL7835413 0.85 ITGB3 (0.51) ITGB3ITGAVITGB1ITGA5MDM2
SCHEMBL7836879 0.84 ITGB3 (0.44) ITGB3ITGAVITGB1ITGA5MDM2
SCHEMBL7833841 0.83 ITGB3 (0.49) ITGB3ITGAVITGB1ITGA5MDM2
SCHEMBL7338411 0.83 ITGB3 (0.54) ITGB3ITGAVITGB1ITGA5MDM4
SCHEMBL6776967 0.83 ITGB3 (0.48) ITGB3ITGAVITGB1ITGA5MDM2
SCHEMBL6778594 0.83 ITGB3 (0.48) ITGB3ITGAVITGB1ITGA5MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP claimed
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed